Hepatocyte Growth Factor-Like protein (HGFL), also known as Macrophage-Stimulating Protein (MSP), is a serum protein produced predominantly by the liver. It plays a significant role in various physiological processes, including tissue regeneration, immune response, and embryonic development.HGFL is a member of the plasminogen-related growth factor family and functions as a ligand for the Ron receptor tyrosine kinase (also known as MST1R). It is synthesized as a single-chain inactive precursor that is cleaved into a biologically active, disulfide-linked two-chain entity. The alpha chain of HGFL binds to the Ron receptor, and the beta chain is responsible for the protein's activation.
Upon binding and activation, HGFL initiates a cascade of intracellular signals leading to various cellular responses. These responses include cell proliferation, motility, survival, and differentiation, which are crucial for tissue repair and regeneration.Interestingly, HGFL and the Ron receptor have been implicated in cancer pathogenesis. Abnormal activation of the Ron receptor by HGFL has been observed in various cancers, leading to tumor growth, invasion, and metastasis. This makes HGFL a potential target for intervention in cancer.Further, HGFL plays a role in immune regulation, with studies showing its involvement in the suppression of inflammatory responses and the promotion of tissue repair during inflammation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Inhibits multiple tyrosine kinases including c-Met, potentially affecting HGFL-related pathways. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $127.00 $192.00 $269.00 $502.00 $717.00 $1380.00 $2050.00 | 114 | |
Inhibits STAT3, a downstream effector of Ron, thus indirectly influencing HGFL signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor that targets several pathways, potentially affecting HGFL-Ron signaling indirectly. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Targets multiple receptor tyrosine kinases, including c-Met, potentially affecting HGFL-related signaling. | ||||||
INCB28060 | 1029712-80-8 | sc-364510 sc-364510A | 10 mg 50 mg | $305.00 $750.00 | ||
A selective c-Met inhibitor, might have indirect effects on HGFL signaling pathways. | ||||||
FK-866 | 658084-64-1 | sc-205325 sc-205325A | 5 mg 10 mg | $140.00 $245.00 | 12 | |
A specific inhibitor of c-Met, can indirectly affect HGFL-Ron signaling. | ||||||